A Review from the Standpoint of Multi - Omics and Microbial - Host Interaction on the Mechanisms, Diagnosis, and Novel Therapeutic Strategies for Inflammatory Bowel Disease

Jiahao Wang

doi:10.54254/2753-8818/2026.33328

Article Information

Received: 1 April 2026

Published: 11 May 2026

DOI: https://doi.org/10.54254/2753-8818/2026.33328

Article Type: Research Article

Cite this article

Wang,J. (2026). A Review from the Standpoint of Multi - Omics and Microbial - Host Interaction on the Mechanisms, Diagnosis, and Novel Therapeutic Strategies for Inflammatory Bowel Disease. Theoretical and Natural Science,170,126-138.

Data availability

The datasets used and/or analyzed during the current study will be available from the authors upon reasonable request.

Disclaimer/Publisher's Note

The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of EWA Publishing and/or the editor(s). EWA Publishing and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

About this Volume

Volume Title: TNS Vol.170

Part of Series: Theoretical and Natural Science

ISSN: 2753-8818 (Print) / 2753-8826 (Online)

Copyright & License

[1]Torres, J., Ungaro, R. C., & Colombel, J. F. (2021). Is prevention the best way to modify inflammatory bowel disease? How close are we? Gastroenterology. https: //doi.org/10.1053/j.gastro.2021.07.051

[2]Luis, A. S., & Hansson, G. C. (2023). Intestinal mucus and their glycans: A habitat for thriving microbiota. Cell Host & Microbe, 31, 1087--1100.

[3]Inaba, R., Vujakovic, S., & Bergstrom, K. (2023). The gut mucus network: A dynamic liaison between microbes and the immune system. Seminars in Immunology, 69, 101807.

[4]Qin, J., et al. (2010). A human gut microbial gene catalogue established by metagenomic sequencing. Nature, 464, 59--65.

[5]Manichanh, C., et al. (2006). Reduced diversity of faecal microbiota in Crohn's disease revealed by a metagenomic approach. Gut, 55, 205--211.

[6]Gilbert, J. A., et al. (2018). Current understanding of the human microbiome. Nature Medicine, 24, 392--400.

[7]El Kaoutari, A., Armougom, F., Gordon, J. I., Raoult, D., & Henrissat, B. (2013). The abundance and variety of carbohydrate-active enzymes in the human gut microbiota. Nature Reviews Microbiology, 11, 497--504.

[8]Briliute, J., et al. (2019). Complex N-glycan breakdown by gut Bacteroides involves an extensive enzymatic apparatus encoded by multiple co-regulated genetic loci. Nature Microbiology, 4, 1571--1581.

[9]Koropatkin, N. M., Cameron, E. A., & Martens, E. C. (2012). How glycan metabolism shapes the human gut microbiota. Nature Reviews Microbiology, 10, 323--335.

[10]Newburg, D. S., & Morelli, L. (2015). Human milk and infant intestinal mucosal glycans guide succession of the neonatal intestinal microbiota. Pediatric Research, 77, 115--120.

[11]Norman, J. M., et al. (2015). Disease-specific alterations in the enteric virome in inflammatory bowel disease. Cell, 160, 447--460.

[12]Adiliaghdam, F., et al. (2022). Human enteric viruses autonomously shape inflammatory bowel disease phenotype through divergent innate immunomodulation. Science Immunology, 7, eabn6660.

[13]Clooney, A. G., et al. (2019). Whole-virome analysis sheds light on viral dark matter in inflammatory bowel disease. Cell Host & Microbe, 26, 764--778.e5.

[14]Torres, J., et al. (2020). Serum biomarkers identify patients who will develop inflammatory bowel diseases up to 5 years before diagnosis. Gastroenterology, 159, 96--104.

[15]Standaert-Vitse, A., et al. (2006). Candida albicans is an immunogen for anti-Saccharomyces cerevisiae antibody markers of Crohn's disease. Gastroenterology, 130, 1764--1775.

[16]Frank, D. N., et al. (2007). Molecular-phylogenetic characterization of microbial community imbalances in human inflammatory bowel diseases. Proceedings of the National Academy of Sciences, 104, 13780--13785.

[17]Martinez-Medina, M., et al. (2014). Western diet induces dysbiosis with increased E coli in CEABAC10 mice, alters host barrier function favouring AIEC colonisation. Gut, 63, 116--124.

[18]Khan, M. T., et al. (2023). Synergy and oxygen adaptation for development of next-generation probiotics. Nature, 620, 381--385.

[19]Matijašić, M., et al. (2020). Gut microbiota beyond bacteria-mycobiome, virome, archaeome, and eukaryotic parasites in IBD. International Journal of Molecular Sciences, 21, 2668.

[20]Baldelli, V., Scaldaferri, F., Putignani, L., & Del Chierico, F. (2021). The role of Enterobacteriaceae in gut microbiota dysbiosis in inflammatory bowel diseases. Microorganisms, 9, 697.

[21]Tanoue, T., et al. (2019). A defined commensal consortium elicits CD8 T cells and anti-cancer immunity. Nature, 565, 600--605.

[22]Lagomarsino, V. N., Kostic, A. D., & Chiu, I. M. (2020). Mechanisms of microbial--neuronal interactions in pain and nociception. Neurobiology of Pain, 9, 100056.

[23]Zhang, Y., et al. (2022). Discovery of bioactive microbial gene products in inflammatory bowel disease. Nature, 606, 754--760.

[24]Metwaly, A., Reitmeier, S., & Haller, D. (2022). Microbiome risk profiles as biomarkers for inflammatory and metabolic disorders. Nature Reviews Gastroenterology & Hepatology, 19, 383--397.

[25]Abraham, C., & Cho, J. H. (2009). Inflammatory bowel disease. New England Journal of Medicine, 361, 2066--2078.

[26]Lloyd-Price, J., et al. (2019). Multi-omics of the gut microbial ecosystem in inflammatory bowel diseases. Nature, 569, 655--662.

[27]Mirsepasi-Lauridsen, H. C., Vallance, B. A., Krogfelt, K. A., & Petersen, A. M. (2019). Escherichia coli pathobionts associated with inflammatory bowel disease. Clinical Microbiology Reviews, 32, e00060--18.

[28]Palmela, C., et al. (2018). Adherent-invasive Escherichia coli in inflammatory bowel disease. Gut, 67, 574--587.

[29]Machiels, K., et al. (2014). A decrease of the butyrate-producing species Roseburia hominis and Faecalibacterium prausnitzii defines dysbiosis in patients with ulcerative colitis. Gut, 63, 1275--1283.

[30]Vich Vila, A., et al. (2018). Gut microbiota composition and functional changes in inflammatory bowel disease and irritable bowel syndrome. Science Translational Medicine, 10, eaap8914.

[31]Barrios-Villa, E., et al. (2020). Comparative genomics of a subset of adherent/invasive Escherichia coli strains isolated from individuals without inflammatory bowel disease. Genomics, 112, 1813--1820.

[32]Goto, Y., et al. (2014). Innate lymphoid cells regulate intestinal epithelial cell glycosylation. Science, 345, 1254009.

[33]Bergstrom, K., et al. (2016). Defective intestinal mucin-type O-glycosylation causes spontaneous colitis-associated cancer in mice. Gastroenterology, 151, 152--164.e11.

[34]Craviotto, V., et al. (2021). Viral infections in inflammatory bowel disease: Tips and tricks for correct management. World Journal of Gastroenterology, 27, 4276--4297.

[35]Irving, P. M., & Gibson, P. R. (2008). Infections and IBD. Nature Clinical Practice Gastroenterology & Hepatology, 5, 18--27.

[36]Jain, U., et al. (2021). Debaryomyces is enriched in Crohn's disease intestinal tissue and impairs healing in mice. Science, 371, 1154--1159.

[37]Schalich, K. M., et al. (2024). A human milk oligosaccharide prevents intestinal inflammation in adulthood via modulating gut microbial metabolism. mBio, 15, e0029824.

[38]Alves, I., et al. (2023). Host-derived mannose glycans trigger a pathogenic γδ T cell/IL-17a axis in autoimmunity. Science Translational Medicine, 15, eabo1930.

[39]Gaifem, J., et al. (2024). A unique serum IgG glycosylation signature predicts development of Crohn's disease and is associated with pathogenic antibodies to mannose glycan. Nature Immunology. https: //doi.org/10.1038/s41590-024-01916-8

[40]Dotan, I., et al. (2006). Antibodies against laminaribioside and chitobioside are novel serologic markers in Crohn's disease. Gastroenterology, 131, 366--378.

[41]Lee, S. H., et al. (2021). Anti-microbial antibody response is associated with future onset of Crohn's disease independent of biomarkers of altered gut barrier function, subclinical inflammation, and genetic risk. Gastroenterology, 161, 1540--1551.

[42]Agus, A., Planchais, J., & Sokol, H. (2018). Gut microbiota regulation of tryptophan metabolism in health and disease. Cell Host & Microbe, 23, 716--724.

[43]Doron, I., et al. (2021). Mycobiota-induced IgA antibodies regulate fungal commensalism in the gut and are dysregulated in Crohn's disease. Nature Microbiology, 6, 1493--1504.

[44]Doron, I., et al. (2021). Human gut mycobiota tune immunity via CARD9-dependent induction of anti-fungal IgG antibodies. Cell, 184, 1017--1031.e14.

[45]Bacher, P., et al. (2019). Human anti-fungal Th17 immunity and pathology rely on cross-reactivity against Candida albicans. Cell, 176, 1340--1355.e15.

[46]Ananthakrishnan, A. N., et al. (2017). Gut microbiome function predicts response to anti-integrin biologic therapy in inflammatory bowel diseases. Cell Host & Microbe, 21, 603--610.e3.

[47]Lee, J. W. J., et al. (2021). Multi-omics reveal microbial determinants impacting responses to biologic therapies in inflammatory bowel disease. Cell Host & Microbe, 29, 1294--1304.e4.

[48]Leonardi, I., et al. (2020). Fungal trans-kingdom dynamics linked to responsiveness to fecal microbiota transplantation (FMT) therapy in ulcerative colitis. Cell Host & Microbe, 27, 823--829.e3.

[49]Björk, J. R., et al. (2024). Longitudinal gut microbiome changes in immune checkpoint blockade-treated advanced melanoma. Nature Medicine, 30, 785--796.

[50]Mills, R. H., et al. (2022). Multi-omics analyses of the ulcerative colitis gut microbiome link Bacteroides vulgatus proteases with disease severity. Nature Microbiology, 7, 262--276.

[51]Byndloss, M. X., et al. (2017). Microbiota-activated PPAR-γ signaling inhibits dysbiotic Enterobacteriaceae expansion. Science, 357, 570--575.

[52]Pierre, J. F., et al. (2023). Peptide YY: A Paneth cell antimicrobial peptide that maintains Candida gut commensalism. Science, 381, 502--508.

[53]Federici, S., et al. (2022). Targeted suppression of human IBD-associated gut microbiota commensals by phage consortia for treatment of intestinal inflammation. Cell, 185, 2879--2898.e24.

[54]Stein-Thoeringer, C. K., et al. (2023). A non-antibiotic-disrupted gut microbiome is associated with clinical responses to CD19-CAR-T cell cancer immunotherapy. Nature Medicine, 29, 906--916.